ONCOTYPE DX AND IHC4 BREAST CANCER TESTS

That this House welcomes the current National Institute for Health and Clinical Excellence (NICE) appraisal of the Oncotype DX and IHC4 breast cancer tests; notes that currently very few breast cancer patients are able to benefit from the test on the NHS due to the cost; recognises that IHC4 is a significantly cheaper test than Oncotype DX and that IHC4 performed equally well when compared with Oncotype DX in the TransATAC dataset; nevertheless also recognises that the Oncotype DX assay has been tested more rigorously with several retrospective studies demonstrating an excellent correlation between the recurrence score, relapse risk and also potential benefit or otherwise from chemotherapy and has the potential to save lives andavoid costly, unnecessary treatment; and therefore urges NICE to approve the test for Oncotype DX and IHC4.